RSS   Newsletter   Contact   Advertise with us

Thermo Fisher to buy Patheon for about $5.2 billion

Share on Twitter Share on LinkedIn
Staff Writer | May 15, 2017
Thermo Fisher Scientific said it would buy Dutch drug ingredients maker Patheon for about $5.2 billion in cash.
Thermo Fisher Scientific
Acquisition   $35 per share
Thermo Fisher's offer of $35 per share represents a premium of about 35 percent to Patheon's Friday close. Patheon shares were up about 33 percent in premarket trading.

The deal represents a purchase price of about $7.2 billion, which includes the assumption of about $2.0 billion of net debt, the companies said in a statement.

Thermo Fisher, which already supplies the biopharmaceutical industry with research, clinical trials and production services, will now have the drug ingredients maker's abilities as drugmakers look to cut costs and reduce clinical trial times.

The transaction, which is expected to be completed by the end of 2017, will immediately add to Thermo Fisher's adjusted profit by 30 cents in the first full year after close.